Design, Synthesis, and Antifungal Activity of Alkyl Gallates Against Plant Pathogenic Fungi In Vitro and In Vivo
作者:Xiao-Long Zhao、Chun-Qing Li、Xiao-Mei Song、Shuang-Mei Yan、Du-Qiang Luo
DOI:10.1007/s10600-021-03276-3
日期:2021.1
A series of alkyl gallates was synthesized by reacting gallic acid with the corresponding alcohols. Their structures were determined on the basis of spectroscopic data, including NMR and MS. The antifungal activities of these compounds against plant pathogenic fungi in vitro and in vivo were assessed.
通过没食子酸与相应的醇反应,合成了一系列没食子酸烷基酯。根据 NMR 和 MS 等光谱数据确定了这些化合物的结构。评估了这些化合物在体外和体内对植物病原真菌的抗真菌活性。
[EN] ANTIMICROBIAL COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSITIONS ANTIMICROBIENNES ET LEURS UTILISATIONS
申请人:NOVUS INT INC
公开号:WO2017004161A1
公开(公告)日:2017-01-05
Antimicrobial compositions comprising sulfur- or selenium-containing, fatty-acylated alpha-hydroxy acid compounds and methods of using said compounds or compositions to inhibit microbial growth.
Processes for the preparation of normorphinan salts
申请人:Wang Peter X.
公开号:US20090156819A1
公开(公告)日:2009-06-18
The invention provides a process for the conversion of opioid derivatives into normorphinan compounds useful for making “nal” compound analgesics and antagonists. In particular, the process may be used for the production of pure normorphinan salts from crude opioid substrates.
The present invention provides cyclic dimers of alpha acids and polymers derived therefrom. Also provided are processes for preparing and methods of using the cyclic dimers and the polymers derived from the cyclic dimers.
[EN] A2-73 CRYSTALLINE POLYMORPH COMPOSITIONS OF MATTER AND METHODS OF USE THEREOF<br/>[FR] COMPOSITIONS POLYMORPHES CRISTALLINES A2-73 DE MATIÈRE ET LEURS PROCÉDÉS D'UTILISATION
申请人:ANAVEX LIFE SCIENCES CORP
公开号:WO2019200345A1
公开(公告)日:2019-10-17
The present disclosure provides crystalline forms of tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine (A2-73), in freebase or salt forms. Also described are pharmaceutical formulations and dosage forms comprising the disclosed crystal forms, and methods of using crystalline A2-73 in dosage forms for neuroprotection including treatment of neurodegenerative and other diseases.